Press releases

Press releases

04 March 2015

Precisions concerning the resupply of Increlex® in the U.S.

03 March 2015  - Paris (France)

Ipsen’s 2014 results and 2015 financial objectives

02 March 2015  - Paris (France)

Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

02 March 2015  - Paris (France)

Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

24 February 2015  - Paris (France)

Ipsen enters into option agreement to acquire Canbex Therapeutics

03 February 2015  - Paris (France)

Ipsen: sales in the fourth quarter and full year 2014

26 January 2015  - Paris (France)

Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

07 January 2015  - Paris (France)

Ipsen announces its corporate agenda for 2015

16 December 2014  - Paris (France)

Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

16 December 2014  - Paris (France)

François Garnier appointed Executive Vice President, General Counsel of Ipsen